Gadovist 1.0 mmol/ml solution for injection
Sponsors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., GE Healthcare Limited, Region Vaesterbotten
Conditions
Cerebrospinal fluid circulation disorder seen in clinically suspected idiopathic normal pressure hydrocephalusCystic fibrosisKawasaki diseasePatients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseasesacute myocardial infarctionand post-cardiac surgery / transplantationbut not limited tocongenital coronary abnormalities
Phase 1
A seamless Phase I/II trial with an initial open-label dose escalation part and a subsequent randomised, double-blind, placebo-controlled expansion part to evaluate the safety, tolerability, and efficacy of a single dose of BI 3720931, an inhaled lentiviral vector gene therapy, in adult people with cystic fibrosis who are ineligible for CFTR modulators (LenticlairTM 1)
SuspendedCTIS2023-503281-23-00
Start: 2024-12-19Target: 12Updated: 2025-07-22
An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Paediatric Patients
Not yet recruitingCTIS2024-515244-22-00
Target: 3Updated: 2025-11-12
Intrathecal contrast-enhanced MRI for investigation of cerebrospinal fluid transportation
Not yet recruitingCTIS2024-520146-33-00
Target: 60Updated: 2025-01-13